The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer

•Hyperthermic intraperitoneal chemotherapy has been proposed within various multimodality strategies for both the prevention and treatment of gastric cancer peritoneal carcinomatosis.•The present work aims to clarify the potential role of hyperthermic intraperitoneal chemotherapy in gastric cancer at different stages of peritoneal disease progression.•A survival advantage of 4 month is seen with the use of HIPEC as a prophylactic strategy.